Harnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy

PLoS ONE

Volumn 3, Issue 5, 2008, Pages

  Arnon, Tal I ^a   Markel, Gal ^b   Bar Ilan, Ahuva ^c   Hanna, Jacob ^d   Fima, Eyal ^c   Benchetrit, Fabrice ^c   Galili, Ruth ^e   Cerwenka, Adelheid ^f   Benharroch, Daniel ^g   Sion Vardy, Netta ^g   Porgador, Angel ^c   Mandelboim, Ofer ^e  

^a CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^e HEBREW UNIVERSITY   (Israel)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G1; IMMUNOMODULATING AGENT; NATURAL KILLER CELL RECEPTOR NKP30 IMMUNOGLOBULIN FUSION PROTEIN; NATURAL KILLER CELL RECEPTOR NKP46D1 IMMUNOGLOBULIN FUSION PROTEIN; NATURAL KILLER CELL RECEPTOR NKP46D2 IMMUNOGLOBULIN FUSION PROTEIN; IMMUNOGLOBULIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MACROPHAGE ACTIVATION; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE HYPERTROPHY; SINGLE DRUG DOSE; TUMOR DIFFERENTIATION; ANIMAL; CELL LINE; CYTOTOXICITY; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IMMUNOTHERAPY; MOUSE MUTANT; NATURAL KILLER CELL; PROSTATE TUMOR; TUMOR CELL LINE;

ANIMALS; CELL LINE; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MALE; MICE; MICE, SCID; PROSTATIC NEOPLASMS; RECEPTORS, IMMUNOLOGIC;

EID: 47749122198     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002150     Document Type: Article

References (42)

1. Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, et al. (2000) Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med 192: 755-760.
2. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991-998.
3. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, et al. (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111.
4. Yokoyama WM (2005) Specific and non-specific natural killer cell responses to viral infection. Adv Exp Med Biol 560: 57-61.
5. Costello RT, Fauriat C, Sivori S, Marcenaro E, Olive D (2004) NK cells: innate immunity against hematological malignancies? Trends Immunol 25: 328-333.
6. Moretta L, Bottino C, Pende D, Mingari MC, Biassoni R, et al. (2002) Human natural killer cells: their origin, receptors and function. Eur J Immunol 32: 1205-1211.
7. Lodoen MB, Lanier LL (2005) Viral modulation of NK cell immunity. Nat Rev Microbiol 3: 59-69.
8. Moretta L, Biassoni R, Bottino C, Mingari MC, Moretta A (2002) Natural killer cells: a mystery no more. Scand J Immunol 55: 229-232.
9. Pende D, Parolini S, Pessino A, Sivori S, Augugliaro R, et al. (1999) Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 190: 1505-1516.
10. Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH (2000) Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 1: 119-126.
11. Mandelboim O, Lieberman N, Lev M, Paul L, Arnon TI, et al. (2001) Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 409: 1055-1060.
12. Arnon TI, Lev M, Katz G, Chernobrov Y, Porgador A, et al. (2001) Recognition of viral hemagglutinins by NKp44 but not by NKp30. Eur J Immunol 31: 2680-2689.
13. Arnon TI, Achdout H, Lieberman N, Gazit R, Gonen-Gross T, et al. (2004) The mechanisms controlling the recognition of tumor and virus infected cells by NKp46. Blood 103: 664-672.
14. Arnon TI, Achdout H, Levi O, Markel G, Saleh N, et al. (2005) Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol 6: 515-523.
15. Sivori S, Vitale M, Morelli L, Sanseverino L, Augugliaro R, et al. (1997) p46, a novel natural killer cell-specific surface molecule that mediates cell activation. J Exp Med 186: 1129-1136.
16. Pessino A, Sivori S, Bottino C, Malaspina A, Morelli L, et al. (1998) Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med 188: 953-960.
17. Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, et al. (1998) NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 187: 2065-2072.
18. Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci MJ, et al. (2002) Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 99: 3661-3667.
19. Gazit R, Gruda R, Elboim M, Arnon TI, Katz G, et al. (2006) Lethal influenza infection in the absence of the natural killer cell receptor gene Ncr1. Nat Immunol 7: 517-523.
20. Carter P (2001) Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 1: 118-129.
21. Blattman JN, Greenberg PD (2004) Cancer immunotherapy: a treatment for the masses. Science 305: 200-205.
22. Shaffer DR, Scher HI (2003) Prostate cancer: a dynamic illness with shifting targets. Lancet Oncol 4: 407-414.
23. Liossis SN, Tsokos GC (2005) Monoclonal antibodies and fusion proteins in medicine. J Allergy Clin Immunol 116: 721-729; quiz 730.
24. Adams JY, Johnson M, Sato M, Berger F, Gambhir SS, et al. (2002) Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging. Nat Med 8: 891-897.
25. Glennie MJ, van de Winkel JG (2003) Renaissance of cancer therapeutic antibodies. Drug Discov Today 8: 503-510.
26. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6: 443-446.
27. Iannello A, Ahmad A (2005) Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev 24: 487-499.
28. Bloushtain N, Qimron U, Bar-Ilan A, Hershkovitz O, Gazit R, et al. (2004) Membrane-Associated Heparan Sulfate Proteoglycans Are Involved in the Recognition of Cellular Targets by NKp30 and NKp46. J Immunol 173: 2392-2401.
29. Hershkovitz O, Jarahian M, Zilka A, Bar-Ilan A, Landau G, et al. (2007) Altered Glycosylation of Recombinant NKp30 Hampers Binding to Heparan Sulfate: a Lesson for the Use of Recombinant Immuno-Receptors as an Immunological Tool. Glycobiology, epub Nov 15.
30. Hershkovitz O, Jivov S, Bloushtain N, Zilka A, Landau G, et al. (2007) Characterization of the Recognition of Tumor Cells by the Natural Cytotoxicity Receptor, NKp44. Biochemistry 46: 7426-7436.
31. Zilka A, Landau G, Hershkovitz O, Bloushtain N, Bar-Ilan A, et al. (2005) Characterization of the heparin/heparan sulfate binding site of the natural cytotoxicity receptor NKp46. Biochemistry 44: 14477-14485.
32. Moretta L, Bottino C, Cantoni C, Mingari MC, Moretta A (2001) Human natural killer cell function and receptors. Curr Opin Pharmacol 1: 387-391.
33. Porgador A (2005) Natural cytotoxicity receptors: pattern recognition and involvement of carbohydrates. Scientific World Journal 5: 151-154.
34. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, et al. (2002) Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 195: 343-351.
35. Coiffier B (2003) Monoclonal antibodies combined to chemotherapy for the treatment of patients with lymphoma. Blood Rev 17: 25-31.
36. Press OW, Leonard JP, Coiffier B, Levy R, Timmerman J (2001) Immunotherapy of Non-Hodgkin's lymphomas. Hematology (Am Soc Hematol Educ Program). pp 221-240.
37. Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, et al. (2002) Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 8: 994-1003.
38. Milas L, Mason K, Hunter N, Petersen S, Yamakawa M, et al. (2000) In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 6: 701-708.
39. Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV (1998) Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci U S A 95: 652-656.
40. Caplan A, Kratz A (2002) Prostate-specific antigen and the early diagnosis of prostate cancer. Am J Clin Pathol 117 Suppl: S104-108.
41. Lowe FC, Nagler EA (2005) Prostate biopsy in the diagnosis of prostate cancer: current trends and techniques. Drugs Today (Barc) 41: 179-191.
42. Swindle P, McCredie S, Russell P, Himmelreich U, Khadra M, et al. (2003) Pathologic characterization of human prostate tissue with proton MR spectroscopy. Radiology 228: 144-151.